As shown in Figure 3, the key gene expression profiling results revealed that Ad-p53 treatment increased the Tumor Inflammation Signature and interferon signaling, decreased TGF-beta and beta-catenin signaling resulting in an increased CD8+ T cell signature which is associated with increased clinical responses to immune checkpoint inhibitor therapy (12). The gene discussed is CD8A; the disease is neoplasm.